Recombinant Human ACOT4 Protein, MYC/DDK-tagged
Cat.No. : | ACOT4-907H |
Product Overview : | Recombinant human ACOT4 protein, fused to MYC/DDK tag at C-terminus, was expressed in HEK293. |
- Specification
- Gene Information
- Related Products
- Download
Source : | HEK293 |
Species : | Human |
Tag : | MYC/DDK |
Form : | 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol. |
Molecular Mass : | 46.1 kDa |
Purity : | > 80% as determined by SDS-PAGE and Coomassie blue staining |
Concentration : | >50 ug/mL as determined by microplate BCA method |
Gene Name : | acyl-CoA thioesterase 4[ Homo sapiens ] |
Official Symbol : | ACOT4 |
Synonyms : | PTE-Ib; PTE1B; PTE2B |
Gene ID : | 122970 |
mRNA Refseq : | NM_152331.3 |
Protein Refseq : | NP_689544 |
MIM : | 614314 |
UniProt ID : | Q8N9L9 |
Products Types
◆ Recombinant Protein | ||
ACOT4-260H | Recombinant Human ACOT4 Protein, His (Fc)-Avi-tagged | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (14)
Ask a questionAs with any new drug development, there are ethical considerations to be taken into account, including issues related to patient safety, access to treatment, and pricing. Additionally, the use of animal models in preclinical testing raises ethical concerns, and efforts should be made to minimize animal suffering and ensure the humane treatment of animals used in research.
Researchers may use ACOT4 protein as a target to screen for potential drugs that inhibit or modulate its activity. Additionally, the protein could be used to test the efficacy of drugs already in development for cancer treatment.
ACOT4 has been implicated in various cancers, including prostate and breast cancer, so potential applications could include developing drugs that target ACOT4 to treat or prevent these types of cancer.
ACOT4 inhibitors are also being studied for their potential to treat metabolic disorders, such as obesity and type 2 diabetes, due to their ability to regulate lipid metabolism. Additionally, ACOT4 has been implicated in neurological disorders, such as Alzheimer's disease, so ACOT4 inhibitors could have potential in these areas as well.
ACOT4 has been identified as a potential target for cancer treatment because it plays a critical role in lipid metabolism, which is essential for cancer cell growth and survival. Inhibiting ACOT4 has been shown to reduce cancer cell growth, induce apoptosis (programmed cell death), and sensitize tumor cells to chemotherapy.
Yes, there are potential applications of ACOT4 in other areas of research. For example, some studies have suggested that ACOT4 may play a role in the regulation of lipid metabolism, which could have implications for cardiovascular disease and other metabolic disorders. Additionally, ACOT4 has been shown to play a role in brain function, so it could potentially be targeted to treat neurological disorders.
ACOT4 inhibitors could be developed as small molecule drugs or antibody therapies that target the protein specifically. Researchers have already identified several compounds that can inhibit ACOT4 activity, and further development and testing is needed to determine their effectiveness as cancer therapies.
There is currently no evidence that ACOT4 protein could be used in diagnostic tests for cancer. However, further research on its role in cancer metabolism and growth could potentially lead to the development of diagnostic tests in the future.
Because there are currently no drugs available that specifically target ACOT4, it is difficult to say what potential side effects or risks could arise from such therapies. However, as with any drug, there could be potential side effects and risks that would need to be carefully considered and evaluated in clinical trials.
ACOT4 is an acyl-CoA thioesterase, which means it catalyzes the hydrolysis of acyl-CoA esters to release free fatty acids. Other enzymes involved in cancer metabolism include lactate dehydrogenase, which converts pyruvate to lactate in order to generate energy, and hexokinase, which catalyzes the first step in glycolysis. While these enzymes all play different roles in cancer metabolism, they are all potential targets for cancer therapies.
There is increasing evidence to suggest that ACOT4 could be used as a prognostic biomarker for certain types of cancer, such as prostate and breast cancer. It could potentially be used to determine the stage and severity of the cancer, as well as to monitor treatment.
There are currently no drugs available that specifically target ACOT4. However, there are drugs that target other enzymes involved in cancer metabolism, such as inhibitors of lactate dehydrogenase.
Researchers use various techniques to study ACOT4 protein, including western blotting, immunofluorescence, and enzyme assays. They may also use CRISPR-Cas9 gene editing technology to knock out ACOT4 in cell lines and study the effects on cancer growth and metabolism. Animal models are also used to study the role of ACOT4 in cancer and other diseases.
One challenge is that ACOT4 is also expressed in normal cells, so any drug that targets it would need to be selective for cancer cells to avoid damaging healthy tissue. Additionally, cancer cells may develop resistance to ACOT4 inhibitors over time, so combination therapies with other drugs may be needed to overcome resistance.
Ask a Question for All ACOT4 Products
Required fields are marked with *
My Review for All ACOT4 Products
Required fields are marked with *
Inquiry Basket